ArticleWorld journal of urology2026
Holmium laser enucleation of the prostate as salvage therapy for benign prostatic obstruction after multiple prior surgical interventions.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salvage surgery after previous BPH procedures: are we comparing technologies or surgical principles?World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecurrent benign prostatic obstruction (BPO) is a recognized complication following surgery. While Holmium laser enucleation of prostate (HoLEP) has been shown to be safe and effective as a salvage option after single procedure, outcomes in patients with multiple prior interventions remain poorly defined. This study aimed to evaluate the outcomes of HoLEP in patients with multiple prior BPO surgeries compared with surgery-naïve individuals.
methodsWe retrospectively reviewed all patients who underwent HoLEP between July 2017 and August 2025. Patients with two or more previous BPO interventions were identified and matched 1:2 with surgery-naïve controls based on age, prostate size, and anticoagulant/antiplatelet status. Baseline characteristics, postoperative outcomes were compared.
resultsAmong 857 patients, 40 with ≥ 2 prior BPO procedures were matched to 72 surgery-naïve controls. Baseline characteristics were largely similar. The control group was significantly frailer with higher modified frailty index scores, lower hemoglobin, higher catheterization rates, and higher residual urine. Both groups experienced significant improvements in voiding. Study group showed more pronounced relief in long term IPSS, but the attrition was high in both groups. Operative time, length of stay, perioperative outcomes, complication rates, and recovery profiles did not differ significantly.
conclusionsHoLEP appears to be a safe and effective treatment option for patients with a history of multiple BPO procedures, yielding functional outcomes and complication rates comparable to surgery-naive individuals. These findings support HoLEP as a viable salvage strategy even after multiple previous prostate surgeries. Nevertheless, the results should be interpreted considering the study's limited sample size, attrition, and the possibility of bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.